Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Roche ’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study ofcrovalimab met primary endpoints of transfusion avoidance andhaemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH)1COMMODORE 3 is the first China-specific study in PNH. Current treatment options are extremely limited in China, resulting in significant levels of disease-related morbidity and mortality for people living with PNH2Based on these datacrovalimab has received Breakthrough Therapy Designation and is under Priority Review for approval in ChinaBasel, 11 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from the phase III COMMO...
Source: Roche Media News - December 11, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study ofcrovalimab met primary endpoints of transfusion avoidance andhaemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH)1COMMODORE 3 is the first China-specific study in PNH. Current treatment options are extremely limited in China, resulting in significant levels of disease-related morbidity and mortality for people living with PNH2Based on these datacrovalimab has received Breakthrough Therapy Designation and is under Priority Review for approval in ChinaBasel, 11 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from the phase III COMMO...
Source: Roche Investor Update - December 11, 2022 Category: Pharmaceuticals Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Implementing Reticulocyte Hemoglobin Into Hematology Algorithms Implementing Reticulocyte Hemoglobin Into Hematology Algorithms
Might reticulocyte hemoglobin, a potentially more clinically stable analyte than ferritin, be useful in screening for iron deficiency and iron-deficiency anemia?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2022 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Congenital Disorders of Red Blood Cells
This article highlights fetal and neonatal erythropoiesis and the underlying etiologies of the inherited red blood cell disorders, as well as reviews the appropriate diagnostic evaluation and next steps in management. It is imperative that neonatal clinicians remain informed about these disorders to enable early recognition and treatment, and ultimately to improve outcomes in affected infants. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - December 1, 2022 Category: Pediatrics Source Type: news
Do you have pallor? It could be a sign of iron deficiency anaemia - other symptoms to spot
Iron forms a key part of your body's overall health and how it functions, becoming low in it can cause complications. (Source: Daily Express - Health)
Source: Daily Express - Health - November 30, 2022 Category: Consumer Health News Source Type: news
AMC Networks To Cut 20% Of U.S. Workforce As Cord Cutting, Streaming Costs, Economic Jitters Roil Media
A media sector squeezed by streaming losses, anemic stocks, layoffs and executive turmoil unveiled its latest casualties Tuesday: 20% of AMC Networks’ U.S. staff, or about 200 people, along with the departure of CEO Christina Spade. The news follows Bob Chapek’s equally sudden departure last…#amcnetworks #amc #christinaspade #streaming #sectorsqueezed #disney #streaminglosses #networks #departure #spade (Source: Reuters: Health)
Source: Reuters: Health - November 30, 2022 Category: Consumer Health News Source Type: news
The IFS Deaton Review of Inequalities: health inequalities
This report finds that there are marked differences in life expectancy between the regions of England, the countries in the UK, and the UK and other wealthy countries. It argues that the austerity measures enacted after the financial crisis of 2008 not only harmed many people directly and unequally, through reductions in public services, but may also have played a role in the anaemic reduction in mortality rates observed for adults after 2010. For policy to improve the health of those left behind to be properly implemented, more and better data is needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 28, 2022 Category: Consumer Health News Source Type: news
The stock market in 2023 will have less pain but no gains as companies see anemic earnings growth, Goldman Sachs says
Poor earnings growth will stretch into 2023, meaning investors should prepare for a year with no gains, Goldman Sachs said. - That's because high interest rates will continue to weigh on corporate earnings well into next year. - If the economy sees a soft landing, earnings will be flat and the S&P…#goldmansachs #goldman #sachs #cost #softlanding #inflation #landing #goldmanestimates #hikes #gains (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2022 Category: Consumer Health News Source Type: news
How is Endometriosis Diagnosed?
Discussion
Endometriosis is classically defined as endometrial tissue occurring outside the uterine lining. It is a common cause of chronic pelvic pain and dysmenorrhea in adolescents. It can present differently in adolescents than adult women and usually can appear like many other common problems such as chronic constipation or gastrointestinal dysmotility. It is estimated that ~25-38% of adolescents with chronic pelvic pain have endometriosis. Use of clinical criteria versus laparoscopic documentation of disease makes the epidemiology of this problem more challenging.
The cause is not wholly agreed upon but many believe ...
Source: PediatricEducation.org - November 28, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Doctors thought boy had leukemia, he was just drinking too much milk
Too much milk can have severe consequences, an
Oregon mom learned. Her two-year-old son who drank double the daily recommended amount of milk became severely anemic. (Source: the Mail online | Health)
Source: the Mail online | Health - November 21, 2022 Category: Consumer Health News Source Type: news
A cell biologist shares the wonder of researching life's most fundamental form
Physician Siddhartha Mukherjee explains how cellular science could lead to breakthroughs in the treatment of cancer, HIV, Type 1 diabetes and sickle cell anemia. His new book is The Song of the Cell.(Image credit: Simon & Schuster) (Source: NPR Health and Science)
Source: NPR Health and Science - November 21, 2022 Category: Consumer Health News Authors: Terry Gross Source Type: news
Campaigners call for new mothers to receive a GP check-up nine months after giving birth
Mary Broddle, 45, from Nottingham lost more than a litre of blood when she gave birth to her son Leo, pictured. She went onto develop severe anaemia which caused major problems. (Source: the Mail online | Health)
Source: the Mail online | Health - November 19, 2022 Category: Consumer Health News Source Type: news
